Ligand Pharmaceuticals Incorporated (LGND) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
| Previous Close | 312.01 |
| Open | 314.81 |
| Day High | 319.81 |
| Day Low | 308.76 |
| 52-Week High | 320.99 |
| 52-Week Low | 112.83 |
| Volume | 363,113 |
| Average Volume | 321,456 |
| Market Cap | 6.4B |
| PE | 38.32 |
| EPS | 8.34 |
| Moving Average 50 Days | 244.59 |
| Moving Average 200 Days | 207.36 |
| Change | 7.54 |
Ligand to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
GlobeNewswire Inc.
Feb 12, 2026 12:00 PM GMT
JUPITER, Fla., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report fourth quarter and full year 2025 financial results on Thursday, February 26, 2026. The company will hold a conf
Ligand to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
GlobeNewswire Inc.
Feb 04, 2026 12:00 PM GMT
JUPITER, Fla., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will participate in a fireside chat at the Oppenhe
Ligand Hosts 2025 Investor Day and Introduces 2026 Guidance
GlobeNewswire Inc.
Dec 09, 2025 12:00 PM GMT
Introduces 2026 full year revenue guidance of $245 million to $285 million, an approximately 15% increase in core revenue growth over 2025, royalty revenue of $200 to $225 million, a 40% increase over 20251, and core adjusted earnings per diluted sha